×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Financial Markets | Health Topics | Infrastructure | Money | Vaccines | Pfizer

Pfizer to Supply US Government 10 Million More Paxlovid Pills

Pfizer Paxlovid
(AP)

Tuesday, 04 January 2022 12:27 PM

Pfizer Inc. said on Tuesday the U.S. government had agreed to buy additional 10 million courses of its COVID-19 oral therapy, Paxlovid, bringing the total order by the government to 20 million courses.

The details of the expanded deal were not disclosed by the company. But for the first order of 10 million courses by the government in November, it had said it would pay Pfizer $5.29 billion.

Pfizer's drug, Paxlovid, was authorized last month for people aged 12 and older. It has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.

About 10 million Paxlovid treatment courses have been accelerated for delivery by the end of June, with the remaining order to follow by the end of September, Pfizer said.

A rival antiviral pill from Merck & Co also won regulatory authorization last month. The U.S. government has a deal for as many as 5 million courses of the pill, molnupiravir, at a price of $700 per course.

© 2022 Thomson/Reuters. All rights reserved.


StreetTalk
Pfizer Inc. said on Tuesday the U.S. government had agreed to buy additional 10 million courses of its COVID-19 oral therapy, Paxlovid, bringing the total order by the government to 20 million courses.
Pfizer, COVID-19 pill Paxlovid
173
2022-27-04
Tuesday, 04 January 2022 12:27 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved